Abstract

A FORMULA FOR PREVENTING CARDIOVASCULAR DISEASE IN HEALTHY INDIVIDUALS AT RISK

Saleh A. Al-Suwayeh, Ehab I. Taha and Gamal M. Mahrous*

Abstract

Patients suffering from cardiovascular disease are usually treated with concomitant administration of cholesterol lowering drugs such as atorvastatin, aspirin and beta blockers such as propranolol HCl. Therefore, the objective of this project is to formulate and evaluate a single oral tablet containing three drugs (atorvastatin, aspirin and propranolol HCl) as an alternative of giving the three drugs in three separate tablets. The interaction of aspirin with both chosen drugs was studied by using Fourier Transformer Infrared (FT -IR) spectroscopy and differential scanning calorimetry (DSC). The DSC traces depicted lowering of melting points of aspirin and atorvastatin by the action of each one on the other during heating. However, FT -IR results revealed that there is no molecular interaction between aspirin and either atorvastatin or propranolol HCl in the solid state. Quantitative detection of the three individual drugs in presence of each other in the prepared tablet was determined by using HPLC method. It was found that the HPLC method is sensitive, reproducible and valid for determination of atorvastatin, aspirin and propranolol HCl in the triple tablet form. Comparative dissolution studies were conducted to compare dissolution of the three drugs in the triple tablet to the individual commercial tablets. Successful comparative dissolution studies assured promising triple drug combination tablet for prevention of cardiovascular diseases and for improving patient compliance during treatment of cardiovascular diseases.

Keywords: Atorvastatin, Aspirin, Propranolol HCl, Cardiovascular diseases and Preventive medicine.